A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk (Q38433805)

3 September 2017

1 reference

title

A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk (English)

1 reference

3 September 2017

Icilma V Fergus

1

1 reference

3 September 2017

Kenneth L Connell

series ordinal

2

1 reference

3 September 2017

Keith C Ferdinand

series ordinal

3

1 reference

3 September 2017

1 June 2015

1 reference

Current cardiology reports

3 September 2017

1 reference

3 September 2017

17

1 reference

3 September 2017

6

1 reference

3 September 2017

38

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-015-0592-x

3 September 2017

0 references

cites work

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Vasodilating versus first-generation β-blockers for cardiovascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

21 January 2018

β-Adrenergic blockers

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

USE OF PROPRANOLOL (INDERAL) IN TREATMENT OF HYPERTENSION.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Nebivolol: impact on cardiac and endothelial function and clinical utility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Antihypertensive drugs and glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

The efficacy and tolerability of nebivolol in hypertensive African American patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-015-0592-X

The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group

21 January 2018

1 reference

12 December 2020

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

1 reference

12 December 2020

Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure

1 reference

12 December 2020

Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension

1 reference

12 December 2020

Effects of bucindolol on neurohormonal activation in congestive heart failure

1 reference

12 December 2020

Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress

1 reference

12 December 2020

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension.

1 reference

12 December 2020

Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression

1 reference

12 December 2020

The Metabolic Syndrome in African Americans: a review.

1 reference

12 December 2020

10.1007/S11886-015-0592-X

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference